Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Novel Prediction Score for Postoperative Acute Renal Failure (ARF) Following Liver Resection (StV 11-2008)

This study has been completed.
Sponsor:
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00743132
First received: August 27, 2008
Last updated: January 22, 2010
Last verified: January 2010
  Purpose

ARF is a frequent event after hepatic resection and therefore clinically highly relevant.

There is limited evidence on the incidence of postoperative ARF and its clinical relevance in patients undergoing liver resection.

This study will evaluate the incidence of acute renal failure (ARF) after liver resection and its impact on postoperative mortality.


Condition
Acute Renal Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Novel Prediction Score for Postoperative Acute Renal Failure (ARF) Following Liver Resection

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Predictor score [ Designated as safety issue: Yes ]
  • Incidence of ARF Length of hospital stay [ Designated as safety issue: Yes ]

Enrollment: 569
Study Start Date: April 2008
Study Completion Date: December 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Postoperative no renal dysfunction
2
Postoperative renal dysfunction

Detailed Description:

ARF is a frequent event after hepatic resection and therefore clinically highly relevant.

There is limited evidence on the incidence of postoperative ARF and its clinical relevance in patients undergoing liver resection.

This study will evaluate the incidence of acute renal failure (ARF) after liver resection and its impact on postoperative mortality.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with benign and malign liver diseases of the Swiss HPB (Hepato-Pancreato-Biliary) Center undergoing liver resection from 2002 - 2007

Criteria

Inclusion Criteria:

  • Patient age >/= 18 years
  • Benign and malign liver diseases

Exclusion Criteria:

  • Trauma cases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00743132

Locations
Switzerland
Swiss HPB (Hepato-Pancreato-Biliary) Center of the University Hospital Zurich
Zurich, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
  More Information

No publications provided by University of Zurich

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: med. pract. Ksenija Slankamenac, Swiss HPB (Hepato-Pancreato-Biliary) Center, Department of Surgery
ClinicalTrials.gov Identifier: NCT00743132     History of Changes
Other Study ID Numbers: StV 11-2008, StV 11-2008
Study First Received: August 27, 2008
Last Updated: January 22, 2010
Health Authority: Switzerland: Ethikkommission

Keywords provided by University of Zurich:
evaluation
incidence
liver surgery
resection
impact
postoperative
mortality

Additional relevant MeSH terms:
Acute Kidney Injury
Renal Insufficiency
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on November 27, 2014